Shandong Longlive Bio-Technology Co., Ltd. (SZSE:002604) agreed to acquire Xiamen Kuaiyun Information Technology Co., Ltd. from Huang Xiaorong and Yang Feng for CNY 580 million on November 23, 2015. As consideration, Shandong Longlive Bio-Technology Co., Ltd. will pay CNY 232 million in cash and will issue 29.52 million shares at CNY 11.79 per share. In a related transaction, Shandong Longlive Bio-Technology Co., Ltd. (SZSE:002604) agreed to acquire Zhaorong Lianhe (Beijing) Technology Development Co., Ltd. from Zhang Dong and Sheng Yong for approximately CNY 1 billion. Shandong Longlive Bio-Technology Co., Ltd. will fund the cash consideration via a private placement of its shares, generating proceeds of CNY 509.5 million. Xiamen Kuaiyun Information Technology Co., Ltd. reported total assets of CNY 9.26 million, total owner’s equity of CNY 3.88 million, revenue of CNY 18.59 million and net profit of CNY 3.15 million for the year ending December 31, 2014. The transaction is subject to approval from the shareholders of Shandong Longlive Bio-Technology Co., Ltd. and approval from the China Securities Regulatory Commission. The Board of Shandong Longlive Bio-Technology approved the deal on November 23, 2015. On March 28, 2016, the shareholders’ of Shandong Longlive Bio-Technology Co., Ltd approved the transaction. On April 13, 2016, China Securities Regulatory Commission Listed Company Merger and Acquisitions Committee approved the transaction. Huaying Securities Co., Ltd. acted as financial advisor, JunZeJun Law Offices acted as legal advisor and BDO China SHU LUN PAN Certified Public Accountants LLP acted as accountants for Shandong Longlive Bio-Technology Co., Ltd. Shandong Longlive Bio-Technology Co., Ltd. (SZSE:002604) completed the acquisition of Xiamen Kuaiyun Information Technology Co., Ltd. from Huang Xiaorong and Yang Feng on May 16, 2016.